Minouk J. Schoemaker

preprint 2021

Prognostic and Immunological Significance of ARID1A Status in Endometriosis-Associated Ovarian Carcinoma

·doi:10.1101/2021.09.16.21262993

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumor suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory repo…

article 2021

Validated biomarker assays confirm that ARID1A loss is confounded with MMR deficiency, CD8 + TIL infiltration, and provides no independent prognostic value in endometriosis‐associated ovarian carcinomas

The Journal of Pathology ·doi:10.1002/path.5849

Abstract ARID1A (BAF250a) is a component of the SWI/SNF chromatin modifying complex, plays an important tumour suppressor role, and is considered prognostic in several malignancies. However, in ovarian carcinomas there are contradictory rep…

2017

Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer.

Nature genetics ·doi:10.1038/ng.3826

To identify common alleles associated with different histotypes of epithelial ovarian cancer (EOC), we pooled data from multiple genome-wide genotyping projects totaling 25,509 EOC cases and 40,941 controls. We identified nine new susceptib…

2016

No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer.

Gynecologic Oncology ·doi:10.1016/j.ygyno.2015.04.034

ObjectiveClinical genetic testing is commercially available for rs61764370, an inherited variant residing in a KRAS 3' UTR microRNA binding site, based on suggested associations with increased ovarian and breast cancer risk as well as with …